ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia | Children’s Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD | Reach Grants | 2015 | California |
A Novel Target for Neuroblastoma Treatment | Beckman Research Institute of City of Hope / Linda Malkas, Ph.D. | Reach Grants | 2014 | California |
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma | The Johns Hopkins University School of Medicine / David Loeb, MD, PhD | Reach Grants | 2013 | Maryland |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition | Children’s Hospital of Philadelphia / Yael Mossé, MD | Reach Grants | 2013 | Pennsylvania |
Epigenomics of High Risk Pediatric T Cell Leukemia | New York University School of Medicine / Iannis Aifantis, PhD | Reach Grants | 2013 | New York |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma | University of Virginia, School of Medicine / Michael Engel, MD/PhD | Reach Grants | 2016 | Virginia |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG | Mayo Clinic / David Daniels, MD/PhD | Reach Grants | 2021 | Minnesota |
Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma | University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD | Reach Grants | 2017 | North Carolina |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma | City of Hope National Medical Center / Linda Malkas, PhD | Reach Grants | 2019 | California |
Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma | Van Andel Research Institute / Patrick Grohar, MD, PhD | Reach Grants | 2013 | Michigan |